Robert Wasserman
Stock Analyst at Benchmark
(3.52)
# 925
Out of 4,761 analysts
112
Total ratings
51.02%
Success rate
4.86%
Average return
Main Sectors:
Stocks Rated by Robert Wasserman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ITGR Integer Holdings | Maintains: Buy | $140 → $150 | $129.87 | +15.50% | 10 | Feb 21, 2025 | |
| HALO Halozyme Therapeutics | Reiterates: Buy | $75 | $57.75 | +29.87% | 8 | Feb 20, 2025 | |
| LGND Ligand Pharmaceuticals | Reiterates: Buy | $135 | $120.67 | +11.88% | 10 | Dec 23, 2024 | |
| BLFS BioLife Solutions | Reiterates: Buy | $30 | $26.67 | +12.49% | 6 | Dec 19, 2024 | |
| ANEB Anebulo Pharmaceuticals | Reiterates: Speculative Buy | $8 | $1.26 | +534.92% | 6 | Nov 19, 2024 | |
| OABI OmniAb | Reiterates: Buy | $8 | $3.65 | +119.18% | 7 | Nov 14, 2024 | |
| NEPH Nephros | Reiterates: Speculative Buy | $5 | $1.53 | +227.50% | 3 | Nov 12, 2024 | |
| EBS Emergent BioSolutions | Maintains: Buy | $8 → $12 | $7.71 | +55.64% | 17 | Nov 7, 2024 | |
| ABCL AbCellera Biologics | Reiterates: Hold | n/a | $3.03 | - | 5 | Nov 5, 2024 | |
| CDXS Codexis | Reiterates: Hold | n/a | $4.18 | - | 7 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Speculative Buy | $5 → $3 | $0.39 | +677.00% | 5 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $95 | $64.92 | +46.33% | 5 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $158.99 | - | 3 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $12 | $2.23 | +438.12% | 6 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $45 | $40.56 | +10.95% | 6 | May 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $4 | $4.08 | -1.96% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $4 | $0.53 | +654.72% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $75 | $1.62 | +4,529.63% | 2 | Apr 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $210.23 | - | 3 | Oct 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $580 | $532.55 | +8.91% | 1 | Jul 16, 2021 |
Integer Holdings
Feb 21, 2025
Maintains: Buy
Price Target: $140 → $150
Current: $129.87
Upside: +15.50%
Halozyme Therapeutics
Feb 20, 2025
Reiterates: Buy
Price Target: $75
Current: $57.75
Upside: +29.87%
Ligand Pharmaceuticals
Dec 23, 2024
Reiterates: Buy
Price Target: $135
Current: $120.67
Upside: +11.88%
BioLife Solutions
Dec 19, 2024
Reiterates: Buy
Price Target: $30
Current: $26.67
Upside: +12.49%
Anebulo Pharmaceuticals
Nov 19, 2024
Reiterates: Speculative Buy
Price Target: $8
Current: $1.26
Upside: +534.92%
OmniAb
Nov 14, 2024
Reiterates: Buy
Price Target: $8
Current: $3.65
Upside: +119.18%
Nephros
Nov 12, 2024
Reiterates: Speculative Buy
Price Target: $5
Current: $1.53
Upside: +227.50%
Emergent BioSolutions
Nov 7, 2024
Maintains: Buy
Price Target: $8 → $12
Current: $7.71
Upside: +55.64%
AbCellera Biologics
Nov 5, 2024
Reiterates: Hold
Price Target: n/a
Current: $3.03
Upside: -
Codexis
Nov 4, 2024
Reiterates: Hold
Price Target: n/a
Current: $4.18
Upside: -
Aug 14, 2024
Maintains: Speculative Buy
Price Target: $5 → $3
Current: $0.39
Upside: +677.00%
Aug 13, 2024
Reiterates: Buy
Price Target: $95
Current: $64.92
Upside: +46.33%
Aug 5, 2024
Reiterates: Hold
Price Target: n/a
Current: $158.99
Upside: -
Jul 11, 2024
Reiterates: Speculative Buy
Price Target: $12
Current: $2.23
Upside: +438.12%
May 29, 2024
Reiterates: Buy
Price Target: $45
Current: $40.56
Upside: +10.95%
Mar 7, 2024
Reiterates: Speculative Buy
Price Target: $4
Current: $4.08
Upside: -1.96%
Mar 6, 2024
Reiterates: Speculative Buy
Price Target: $4
Current: $0.53
Upside: +654.72%
Apr 6, 2023
Reiterates: Speculative Buy
Price Target: $75
Current: $1.62
Upside: +4,529.63%
Oct 24, 2022
Downgrades: Hold
Price Target: n/a
Current: $210.23
Upside: -
Jul 16, 2021
Initiates: Buy
Price Target: $580
Current: $532.55
Upside: +8.91%